Quince Announces OrphAI Acquisition and Up to $187M Private Placement to Advance Pulmonary Pipeline
- 6 hours ago
- 1 min read
South San Francisco, CA, May 18, 2026 (Globe Newswire) -- Quince Therapeutics has announced the acquisition of OrphAI alongside a private financing arrangement valued at up to $187 million. The transaction is designed to support advancement of the company’s pulmonary disease pipeline and broaden its development capabilities. The funding is expected to provide additional resources for clinical progress and future growth initiatives.
Read full article here.





















